Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Diabetic Cardiomyopathies

glucose, (beta-d)-isomer has been researched along with Diabetic Cardiomyopathies in 43 studies

Research

Studies (43)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	27 (62.79)	24.3611
2020's	16 (37.21)	2.80

Authors

Authors	Studies
Hao, W; Li, N; Mi, C; Wang, Q; Yu, Y	1
Asseri, SM; Ebrahim, HA; El-Agawy, MSE; El-Shafey, M; El-Sherbiny, M; Eldosoky, M; Elsherbini, DMA; Elsherbiny, NM	1
Bin-Meferij, MM; Eissa, H; El-Baz, AM; El-Kott, AF; El-Sokkary, MMA; Elgharabawy, RM; Hassan, HM; Khalaf, EM; Khodir, AE; Nouh, NA; Saleh, S; Shata, A; Yousef, ME	1
Chen, SY; Feng, TH; Hao, DD; Miao, HX; Shang, J; Shi, J; Wan, S; Wang, SY; Zhao, Q; Zhou, CH	1
Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD	1
Abraham, NG; Arad, M; Aravot, D; Arow, M; Freimark, D; Hochhauser, E; Kornowski, R; Nudelman, V; Shainberg, A; Waldman, M; Yadin, D	1
Birnbaum, Y; Chen, H; Nylander, S; Tran, D; Yang, HC; Ye, Y	1
Adamski, J; Artati, A; Boor, P; Droste, P; Haj-Yehia, E; Kappel, B; Klinkhammer, BM; Lehrke, M; Lopaschuk, GD; Marx, N; Maxeiner, S; Moellmann, J; Schütt, K; Verma, S	1
Abdel-Moneim, A; Abdul-Hamid, M; Galaly, SR; Mohamed, HM; Mostafa, F	1
Guo, R; Li, Y; Ni, J; Xu, Y	1
Chen, YJ; Cheng, WL; Chung, CC; Huang, SY; Kao, YH; Lee, TI; Lee, TW; Trang, NN	1
Abe, M; Hoshino, K; Kai, T; Nakamura, J; Oka, S; Watanabe, A; Watanabe, K	1
Chen, Y; He, W; Jin, Y; Li, Y; Tian, L; Yao, J	1
Jin, S; Li, Y; Liu, SL; Wei, X; Yang, XY; Zhao, Y	1
An, F; Jin, T; Liu, D; Liu, M; Pan, J; Suo, M; Tian, J; Wang, X; Zhang, M	1
Ding, Y; Du, B; Fu, H; Li, L; Liu, Y; Wang, F; Yin, Y; Yu, S; Yue, Z; Zhang, Z; Zhao, R	1
AboGresha, NM; Ahmed, AAM; El-Sayed, N; El-Sayed, NM; Mahmoud, IZ; Mostafa, YM	1
Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS	1
Bai, YG; Dai, ZJ; Liu, M; Ma, YG; Wang, JW; Xie, MJ	1
Bajaj, M; Birnbaum, Y; Perez-Polo, JR; Yang, HC; Ye, Y	1
Wu, W; Zhou, Y	1
Staels, B	2
Verbrugge, FH	1
Bottari, SP; Daiber, A; Gödtel-Armbrust, U; Hanf, A; Kashani, F; Kopp, M; Kröller-Schön, S; Lackner, KJ; Li, H; Mayoux, E; Münzel, T; Oelze, M; Roohani, S; Schulz, E; Steven, S; Welschof, P; Wenzel, P; Wojnowski, L; Xia, N	1
Birkeland, KI; Bodegard, J; Carstensen, B; Eriksson, JW; Fenici, P; Gulseth, HL; Jørgensen, ME; Nathanson, D; Norhammar, A; Nyström, T; Persson, F; Thuresson, M	1
Brown, AJM; Lang, C; McCrimmon, R; Struthers, A	1
Cheng, Z; Fan, Y; Gu, J; Jiang, S; Li, T; Lv, J; Sun, D; Wang, S; Xiong, Z; Yang, Z; Zhang, M	1
Bjornstad, P; Cherney, DZI; Lovshin, JA; Lytvyn, Y; Udell, JA	1
Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD	1
Covino, J; Hoffman, J	1
Abbate, A; Billingsley, HE; Buckley, LF; Buzzetti, R; Canada, JM; Carbone, S; Christopher, S; Dixon, DL; Kadariya, D; Markley, R; Medina de Chazal, H; Trankle, CR; Van Tassell, BW; Vo, C	1
Deshpande, M; Palaniyandi, SS; Pan, G; Pang, H	1
Cai, ZJ; Dhandhania, V; Lai, WH; Lau, YM; Lee, YK; Ng, KM; Siu, CW; Tse, HF	1
Chen, L; Cheng, Y; Han, F; Li, C; Li, T; Li, X; Liu, X; Lu, Y; Sun, B; Xu, L; Xue, M; Yu, X; Zhang, J	1
Chang, Y; Chen, L; Cheng, Y; Li, T; Li, X; Liu, X; Lu, Y; Sun, B; Wang, Y; Xu, L; Xue, M; Yu, X	1
Packer, M	1
Abdul-Ghani, M; Chilton, R; Clarke, G; DeFronzo, RA; Norton, L; Ryder, RE	1
Huang, B; Jiang, QS; Wu, Y; Xue, L	1
Ayer, A; Cariou, B; Charpentier, F; Dollet, L; Jagu, B; Joubert, M; Le May, C; Magré, J; Manrique, A; Marechal, X; Montaigne, D; Prieur, X; Staels, B; Tesse, A; Toumaniantz, G	1
Fioretto, P; Inzucchi, SE; Vettor, R	1
Gause-Nilsson, I; Johnsson, E; Kosiborod, M; Sonesson, C; Xu, J	1
Alzaid, A	1

Reviews

5 review(s) available for glucose, (beta-d)-isomer and Diabetic Cardiomyopathies

Article	Year
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. The American journal of medicine, 2017, Volume: 130, Issue:6S Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2017
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2017
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. Current heart failure reports, 2017, Volume: 14, Issue:4 Topics: Benzhydryl Compounds; Blood Glucose; Diabetic Cardiomyopathies; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2017
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation, 2017, Oct-24, Volume: 136, Issue:17 Topics: Benzhydryl Compounds; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:5 Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones	2016

Trials

3 trial(s) available for glucose, (beta-d)-isomer and Diabetic Cardiomyopathies

Article	Year
Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC cardiovascular disorders, 2017, 08-23, Volume: 17, Issue:1 Topics: Administration, Oral; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Progression; Double-Blind Method; Glucosides; Humans; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Magnetic Resonance Imaging; Proof of Concept Study; Prospective Studies; Research Design; Risk Factors; Scotland; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling	2017
DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5 Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors	2018
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8 Topics: Benzhydryl Compounds; Body Mass Index; Cardiorespiratory Fitness; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Drug Interactions; Female; Glucosides; Heart; Heart Failure; Humans; Male; Middle Aged; Obesity; Oxygen Consumption; Pilot Projects; Respiratory System; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume	2018

Other Studies

35 other study(ies) available for glucose, (beta-d)-isomer and Diabetic Cardiomyopathies

Article	Year
Salidroside attenuates cardiac dysfunction in a rat model of diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2022, Volume: 39, Issue:3 Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Diabetic Cardiomyopathies; Disease Models, Animal; Glucosides; Inflammation; Male; Myocytes, Cardiac; Oxidative Stress; Phenols; Rats; Rats, Sprague-Dawley; Signal Transduction; Streptozocin; TOR Serine-Threonine Kinases	2022
Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis. Frontiers in endocrinology, 2022, Volume: 13 Topics: Animals; Apoptosis; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Glucosides; Humans; Inflammation; Liraglutide; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors	2022
A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: Role of oxidative stress, gut microbiota, and PPARγ activation. European journal of pharmacology, 2022, Sep-15, Volume: 931 Topics: Animals; Benzhydryl Compounds; Carotenoids; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Gastrointestinal Microbiome; Glucosides; Lactobacillus; Male; Oxidative Stress; PPAR gamma; Rats; Rats, Wistar; Streptozocin	2022
Gut microbiota profiling revealed the regulating effects of salidroside on iron metabolism in diabetic mice. Frontiers in endocrinology, 2022, Volume: 13 Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Gastrointestinal Microbiome; Glucosides; Iron; Mice; Phenols; RNA, Ribosomal, 16S	2022
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 11-05, Volume: 140, Issue:19 Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2019
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovascular diabetology, 2020, 01-10, Volume: 19, Issue:1 Topics: Angiotensin II; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Calcium Channels, L-Type; Calcium Signaling; Cells, Cultured; Diabetes Mellitus; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Glucosides; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Rats, Sprague-Dawley; Sodium-Calcium Exchanger; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Ventricular Function, Left	2020
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:4 Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Disease Progression; Enzyme Activation; Fibrosis; Glucosides; Inflammasomes; Male; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred C57BL; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Purinergic P2Y Receptor Antagonists; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ticagrelor; TOR Serine-Threonine Kinases; Ventricular Function, Left; Ventricular Remodeling	2020
Empagliflozin improves left ventricular diastolic function of db/db mice. Biochimica et biophysica acta. Molecular basis of disease, 2020, 08-01, Volume: 1866, Issue:8 Topics: Amino Acids, Branched-Chain; Animals; Benzhydryl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diet, High-Fat; Glucose; Glucosides; Humans; Hypoglycemic Agents; Ketone Bodies; Male; Mice; Mice, Transgenic; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Ventricular Function, Left	2020
Polydatin and polydatin-loaded chitosan nanoparticles attenuate diabetic cardiomyopathy in rats. Journal of molecular histology, 2021, Volume: 52, Issue:2 Topics: Animals; Antioxidants; Chitosan; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Glucosides; Glycated Hemoglobin; Immunohistochemistry; Male; Nanoparticles; Oxidative Stress; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Stilbenes	2021
Salidroside protects against cardiomyocyte apoptosis and ventricular remodeling by AKT/HO-1 signaling pathways in a diabetic cardiomyopathy mouse model. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 82 Topics: Animals; Apoptosis; Diabetic Cardiomyopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Glucosides; Heme Oxygenase-1; Male; Mice; Myocytes, Cardiac; Phenols; Proto-Oncogene Proteins c-akt; Signal Transduction; Ventricular Remodeling	2021
Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats. International journal of molecular sciences, 2021, Jan-25, Volume: 22, Issue:3 Topics: Animals; Apoptosis; Benzhydryl Compounds; Biomarkers; Cytokines; Diabetic Cardiomyopathies; Disease Models, Animal; Echocardiography; Energy Metabolism; Fatty Acids; Fibrosis; Glucose; Glucosides; Heart Function Tests; Hypoglycemic Agents; Immunohistochemistry; Inflammation Mediators; Liraglutide; Myocardium; Rats; Sodium-Glucose Transporter 2 Inhibitors	2021
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study. BMC cardiovascular disorders, 2021, 04-29, Volume: 21, Issue:1 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left	2021
Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4/NF-κB/NLRP3 and PGC1a/SIRT3 pathways. International immunopharmacology, 2021, Volume: 96 Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Synergism; Flavonoids; Glucosides; Glycosides; Inflammasomes; Male; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenylpropionates; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirtuins; Toll-Like Receptor 4	2021
Salidroside protects cardiac function in mice with diabetic cardiomyopathy via activation of mitochondrial biogenesis and SIRT3. Phytotherapy research : PTR, 2021, Volume: 35, Issue:8 Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Glucosides; Mice; Mitochondria; Myocytes, Cardiac; Organelle Biogenesis; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenols; Rats; Sirtuin 3	2021
Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats. Journal of cellular and molecular medicine, 2021, Volume: 25, Issue:16 Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diet, High-Fat; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibroblasts; Fibrosis; Glucosides; Male; Mesoderm; Rats; Signal Transduction; Smad4 Protein; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta	2021
Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway. Journal of cellular and molecular medicine, 2021, Volume: 25, Issue:15 Topics: Benzhydryl Compounds; Diabetic Cardiomyopathies; Glucosides; Humans; MAP Kinase Signaling System; Molecular Docking Simulation; Network Pharmacology; Protein Interaction Mapping; Sodium-Glucose Transporter 2 Inhibitors	2021
Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats. Chemico-biological interactions, 2021, Sep-25, Volume: 347 Topics: Animals; Benzhydryl Compounds; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Electrocardiography; Erythropoietin; Glucosides; Male; MAP Kinase Signaling System; Myocardium; Rats, Wistar; Streptozocin	2021
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids in health and disease, 2017, Apr-13, Volume: 16, Issue:1 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Salidroside contributes to reducing blood pressure and alleviating cerebrovascular contractile activity in diabetic Goto-Kakizaki Rats by inhibition of L-type calcium channel in smooth muscle cells. BMC pharmacology & toxicology, 2017, 04-26, Volume: 18, Issue:1 Topics: Animals; Blood Glucose; Blood Pressure; Calcium Channels, L-Type; Cells, Cultured; Cerebral Arteries; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Gene Expression Regulation; Glucosides; Hypoglycemic Agents; Male; Muscle Contraction; Muscle, Smooth, Vascular; Phenols; Rats, Inbred WKY; RNA, Messenger; Vasodilation	2017
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovascular drugs and therapy, 2017, Volume: 31, Issue:2 Topics: Adamantane; AMP-Activated Protein Kinases; Animals; Apoptosis; Benzhydryl Compounds; CARD Signaling Adaptor Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fibroblasts; Fibrosis; Glucosides; Hypoglycemic Agents; Inflammasomes; Inflammation Mediators; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Mice, Obese; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Function, Left	2017
The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 41, Issue:6 Topics: Animals; Apoptosis; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucosides; Heat-Shock Proteins; Hemodynamics; Male; Myocardium; Myocytes, Cardiac; Protective Agents; Rats; Rats, Wistar; Sodium-Glucose Transport Proteins; TNF Receptor-Associated Factor 2; Transcription Factor CHOP	2017
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox biology, 2017, Volume: 13 Topics: Animals; Aorta, Thoracic; Benzhydryl Compounds; C-Reactive Protein; Diabetic Cardiomyopathies; Endothelium, Vascular; Glucose; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Oxidative Stress; Rats; Rats, Zucker; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:2 Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators; Middle Aged; Norway; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2; Sweden	2018
Polydatin ameliorates diabetic cardiomyopathy via Sirt3 activation. Biochemical and biophysical research communications, 2017, 11-25, Volume: 493, Issue:3 Topics: Animals; Autophagosomes; Autophagy; Cardiotonic Agents; Diabetic Cardiomyopathies; Glucosides; Mice, Inbred C57BL; Mice, Knockout; Mitochondria, Heart; Myocytes, Cardiac; Sirtuin 3; Stilbenes; Up-Regulation	2017
What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes? JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:3 Topics: Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors	2018
Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians. European journal of pharmacology, 2018, Nov-15, Volume: 839 Topics: Aldehyde Dehydrogenase, Mitochondrial; Aldehydes; Animals; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetic Cardiomyopathies; Glucose Tolerance Test; Glucosides; Humans; Mice; Mutation; Phosphoproteins; Precision Medicine	2018
Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes. Scientific reports, 2018, 10-05, Volume: 8, Issue:1 Topics: Benzhydryl Compounds; Cell Line; Cell Size; Cells, Cultured; Diabetic Cardiomyopathies; Glucose; Glucosides; Humans; Induced Pluripotent Stem Cells; Male; Myocytes, Cardiac; Sodium-Glucose Transporter 2 Inhibitors	2018
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovascular diabetology, 2019, 02-02, Volume: 18, Issue:1 Topics: Animals; Antioxidant Response Elements; Antioxidants; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Glucosides; Mice, Inbred C57BL; Myocardium; NF-E2-Related Factor 2; Oxidative Stress; Phosphorylation; Signal Transduction; Smad Proteins; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling	2019
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clinical science (London, England : 1979), 2019, 08-15, Volume: 133, Issue:15 Topics: Animals; Benzhydryl Compounds; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Glucosides; Heart; Humans; Male; Mice; Oxidative Stress; Signal Transduction; Soluble Guanylyl Cyclase	2019
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Circulation, 2019, 08-06, Volume: 140, Issue:6 Topics: Benzhydryl Compounds; Blood Volume; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics; Glucose; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Multicenter Studies as Topic; Myocardial Infarction; Natriuresis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Stroke; Stroke Volume	2019
[Effect and mechanism of polydatin on diabetic myocardial hypertrophy in mice]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2015, Volume: 40, Issue:21 Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drugs, Chinese Herbal; Glucosides; Humans; Hypertrophy; Insulin; Male; Mice; NF-kappa B; Signal Transduction; Stilbenes	2015
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. Diabetes, 2017, Volume: 66, Issue:4 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Echocardiography; Fluorodeoxyglucose F18; Glucosides; GTP-Binding Protein gamma Subunits; Heart; Heterotrimeric GTP-Binding Proteins; Hyperglycemia; Hypoglycemic Agents; Lipodystrophy; Magnetic Resonance Imaging; Mice; Mice, Knockout; Myocardium; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Ventricular Dysfunction, Left; Ventricular Function	2017
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia, 2017, Volume: 60, Issue:3 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. Journal of diabetes and its complications, 2017, Volume: 31, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics, Osmotic; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Longitudinal Studies; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sodium-Glucose Transport Proteins	2017
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. Diabetes technology & therapeutics, 2017, Volume: 19, Issue:6 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Approval; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Mortality; Multicenter Studies as Topic; Survival Analysis	2017